FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Irbesartan and Hydrochlorothiazide Tablets USP
Status: Discontinuation
»Therapeutic Categories: Cardiovascular

Expand all

Mylan Pharmaceuticals Inc. (New 11/18/2016)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
Irbesartan and Hydrochlorothiazide Tablets USP, 150 mg/12.5 mg, 30s (NDC 0378-3033-93) 11/18/2016 A business decision to discontinue manufacture of the drug. The product discontinuations are not related to product quality, safety or efficacy.
Irbesartan and Hydrochlorothiazide Tablets USP, 300 mg/12.5 mg, 30s (NDC 0378-3034-93) 11/18/2016 A business decision to discontinue manufacture of the drug. The product discontinuations are not related to product quality, safety or efficacy.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English